Joseph Payne, is co-founder, CEO, and chairman of San Diego-based Arcturus Therapeutics, which is advancing proprietary technology for developing RNAi-based drugs targeting orphan diseases. He has over 20 years of successfully drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko. He has over 40 publications and patents and seven investigational new drug candidates.
His academic training includes Brigham Young University (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics Strategy).
Editor’s note: Arcturus CEO Joe Payne is set to give a company presentation Wednesday at the BIO 2014 convention in San Diego. —BVB
Medicinal chemistry has come a long way since... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.